NEWS

By: Dan Leonard, Executive Director, We Work For Health and Chrissy Buteas, President and Chief Executive Officer, HealthCare Institute of New Jersey Making medicines more affordable is a goal we all share. Patients, employers, innovators, and policymakers recognize that high costs can stand between patients and the care they need. But not every policy that promises lower prices delivers better outcomes. If policymakers were to codify a “most favored nation” (MFN) drug pricin

Anyone who has followed the U.S. biopharmaceutical industry closely since the start of last year is likely aware of the historic investment that companies have made to strengthen the nation's drug innovation infrastructure, including through next-generation manufacturing facilities that can deliver therapies to Americans faster and more safely. We Work For Health has tracked more than $582 billion in announcements since January 2025. While it will take time for the full scope

Intellectual property is the backbone of the biopharma industry’s innovation ecosystem, driving the discovery and development of life‑saving treatments for patients. In recent years, We Work For Health has presented the Healthcare Innovation Leadership Award to policymakers who demonstrate a sustained commitment to protecting the intellectual property framework that fuels medical innovation. The latest honorees are Representatives Brad Knott (R-NC) and Scott Fitzgerald (R

On April 23, We Work For Health hosted a webinar to examine how a Most Favored Nation pricing policy could affect patient access, affordability, and medical innovation, and why the promised savings may not materialize. Drawing on real‑world examples from Europe and other OECD countries, panelists discussed the unintended but very real consequences of implementing and codifying an MFN policy, including reduced access to lifesaving medicines and limited or nonexistent price rel

World Intellectual Property Day is this Sunday, April 26, and it comes at a moment of rapid scientific progress and growing global competition. As innovation accelerates, the systems that support investment, collaboration and long‑term research are under increasing pressure. The decisions made now will shape where breakthroughs are developed and how quickly they reach patients. Ahead of World IP Day, WWFH Executive Director Dan Leonard shares his perspective on why intell

Nearly 250 years ago, the United States made a consequential decision about how it would compete, grow and lead. At the nation’s founding was a belief that protecting new ideas would do more than reward individual ingenuity. It would fuel economic growth, encourage risk-taking, and help transform invention into lasting progress. That commitment helped define America’s innovation model and positioned the country for generations of leadership. The nation’s legacy of innov

Effective leadership recognizes that policy decisions do not exist in a vacuum – they shape jobs, economic growth and patient access to life-saving treatments. Virginia Gov. Abigail Spanberger recently put workers, employers and Virginia’s future first, setting an example for how thoughtful policymaking can foster innovation and opportunity. Virginia’s biopharmaceutical sector is in the middle of historic growth. Since 2025, life sciences companies have committed $10B+ in new

Ahead of World Intellectual Property (IP) Day on April 26, We Work For Health Executive Director Dan Leonard issued the following statement: “World Intellectual Property Day is a reminder that medical innovation is the result of deliberate policy choices. In health care, intellectual property determines whether bold ideas are pursued, whether long‑term research is sustained and whether discoveries ultimately reach patients as treatments, diagnostics or cures. The United State